Lulizumab pegol
Lulizumab Pegol
Lulizumab Pegol (pronunciation: loo-liz-oo-mab pe-gol) is a biopharmaceutical drug that is currently under investigation for the treatment of autoimmune diseases. It is a monoclonal antibody that targets the B cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which are involved in the pathogenesis of many autoimmune diseases.
Etymology
The name "Lulizumab Pegol" is derived from the International Nonproprietary Names (INN) system. "Luli-" is a prefix used for monoclonal antibodies that act on the immune system, "-zumab" is a suffix used for humanized antibodies, and "Pegol" indicates that the drug is a PEGylated (polyethylene glycol) molecule, which can improve the drug's stability and half-life.
Mechanism of Action
Lulizumab Pegol works by binding to BAFF and APRIL, two proteins that are overexpressed in many autoimmune diseases. By blocking these proteins, Lulizumab Pegol can reduce the activation and proliferation of B cells, which are responsible for producing the autoantibodies that cause damage in autoimmune diseases.
Clinical Trials
Lulizumab Pegol has been tested in several clinical trials for conditions such as Systemic Lupus Erythematosus and Rheumatoid Arthritis. While results have been promising, further research is needed to fully understand the drug's efficacy and safety profile.
Related Terms
- Monoclonal Antibody
- Autoimmune Disease
- B cell
- Clinical Trial
- Systemic Lupus Erythematosus
- Rheumatoid Arthritis
External links
- Medical encyclopedia article on Lulizumab pegol
- Wikipedia's article - Lulizumab pegol
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski